Can mediastinal radiation therapy cause pulmonary hypertension, and what is the appropriate work‑up and treatment?

Can Mediastinal Radiotherapy Cause Pulmonary Hypertension?

Yes, mediastinal radiotherapy can definitively cause pulmonary hypertension through direct radiation-induced vascular injury and remodeling of the pulmonary vasculature. This is a recognized complication that falls under Group 5 pulmonary hypertension (PH with unclear/multifactorial mechanisms) in the current classification system 1.

Mechanism and Pathophysiology

Radiation causes pulmonary hypertension through several distinct mechanisms:

• Direct pulmonary artery endothelial injury leading to acute endothelial cell loss, followed by progressive vascular remodeling that closely resembles pulmonary arterial hypertension 2, 3
• Pulmonary vascular remodeling with muscularization extending into distal intra-acinar arteries, reduction in peripheral arterial diameter, and decreased number of peripheral vessels 4
• Increased pulmonary vascular resistance that develops even before clinical symptoms appear 2
• The radiation dose to the pulmonary arteries (particularly PA V10 Gy) is the strongest predictor of PH development 5

Critical distinction: This radiation-induced PH appears to occur through a pathophysiological process distinct from radiation-induced pulmonary fibrosis alone 5. The vascular injury is the primary driver, not just secondary lung parenchymal damage.

Risk Factors

Radiation-associated cardiac and pulmonary vascular toxicity risk increases with 6:

• Radiation dose >30-35 Gy (tolerance threshold)
• Dose per fraction >2 Gy
• Large volume of irradiated heart and pulmonary vessels
• Younger age at exposure
• Longer time since exposure (latency period typically 10-15 years)
• Concurrent chemotherapy (especially anthracyclines, alkylating agents, dasatinib)
• Pre-existing cardiovascular risk factors (diabetes, hypertension, dyslipidemia, smoking)

Clinical Presentation and Timeline

The 2-year cumulative incidence of PH after thoracic radiotherapy is approximately 11.6% 5. Key features include:

• Latency period: Vascular changes begin acutely with endothelial loss, but clinical PH typically manifests years after treatment (often >10 years) 6
• Early subclinical phase: Vascular oedema and endothelial cell loss occur even before symptoms develop 2
• Progressive nature: Leads to right ventricular hypertrophy, dysfunction, and eventual right heart failure if untreated 2, 3
• Associated findings: Patients who develop PH post-radiation have higher rates of moderate or greater tricuspid regurgitation (18.7% vs 0.2%) and right ventricular systolic dysfunction (3.3% vs 0.2%) 5

Diagnostic Work-Up

Initial Screening Strategy

For asymptomatic patients with history of mediastinal radiation 7:

• Begin screening at 5 years post-treatment
• Repeat screening at least every 5 years thereafter
• Earlier evaluation if any symptoms develop (dyspnea, fatigue, syncope, chest pain, decreased exercise capacity)

Diagnostic Algorithm

Step 1: Transthoracic Echocardiography 8

• Primary screening tool for detecting PH
• Assess estimated pulmonary artery systolic pressure
• Evaluate right ventricular size, function, and wall thickness
• Look for tricuspid regurgitation and right atrial enlargement
• Assess for pericardial effusion (common radiation complication)

Important caveat: Echocardiography alone is insufficient to accurately determine PA pressure or pulmonary vascular resistance 9. Use it as a screening tool, not for definitive diagnosis.

Step 2: Right Heart Catheterization (RHC) 8, 9

• Gold standard for diagnosis - mandatory for confirming PH and determining hemodynamic subtype
• Perform when echocardiography suggests PH (estimated PASP >35-40 mmHg)
• Required measurements:
  • Mean pulmonary arterial pressure (mPAP): PH defined as >20 mmHg (updated 2018 definition) 8
  • Pulmonary artery wedge pressure (PAWP)
  • Pulmonary vascular resistance (PVR)
  • Cardiac output

Hemodynamic classification 8:

• Precapillary PH: mPAP >20 mmHg, PAWP ≤15 mmHg, PVR ≥3 Wood units
• Isolated postcapillary PH: mPAP >20 mmHg, PAWP >15 mmHg, PVR <3 Wood units
• Combined pre- and postcapillary PH: mPAP >20 mmHg, PAWP >15 mmHg, PVR ≥3 Wood units

Step 3: Additional Imaging 8, 10, 8

• CT chest with IV contrast or CTA chest: Evaluate for chronic thromboembolic disease, assess pulmonary vasculature, detect radiation-induced lung fibrosis
• Ventilation/perfusion (V/Q) scan: Rule out chronic thromboembolic PH (CTEPH) - critical differential diagnosis
• Cardiac MRI: Assess right ventricular function and morphology when echocardiography is suboptimal

Step 4: Exclude Other Causes 8, 1

• Pulmonary function tests with diffusion capacity
• Arterial blood gas
• Overnight oximetry or polysomnography
• Connective tissue disease serologies
• HIV testing
• Liver function tests (portal hypertension)
• Complete blood count (anemia, myeloproliferative disorders)

Monitoring During Follow-Up

For patients already diagnosed with radiation-induced PH 11:

• Perform repeat RHC during follow-up when at intermediate-low, intermediate-high, or high risk of death and when therapeutic consequences are expected
• Regular clinical assessment with functional class determination
• Serial echocardiography to monitor right ventricular function
• 6-minute walk test
• BNP/NT-proBNP levels

Treatment Approach

General Principles

Radiation-induced PH should be managed similarly to other forms of pulmonary arterial hypertension (Group 1 PAH), with treatment guided by risk stratification 1, 12.

Risk Stratification

Classify patients as low, intermediate-low, intermediate-high, or high risk based on:

• WHO functional class
• 6-minute walk distance
• BNP/NT-proBNP levels
• Hemodynamic parameters (right atrial pressure, cardiac index)
• Imaging findings (right ventricular function, pericardial effusion)

Pharmacological Treatment Algorithm

For patients at intermediate-low, intermediate-high, or high risk 11, 13:

Initial therapy (if treatment-naïve):

• Start with combination therapy targeting multiple pathways
• Preferred: Endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitor (PDE-5i) or ERA + prostacyclin pathway agent

Specific agents 1, 14:

• Endothelin receptor antagonists: Bosentan, ambrisentan, macitentan
• PDE-5 inhibitors: Sildenafil, tadalafil
• Prostacyclin pathway: Epoprostenol (IV), treprostinil (IV/SC/inhaled), iloprost (inhaled), selexipag (oral)
• Soluble guanylate cyclase stimulator: Riociguat

Add-on therapy for inadequate response 11:

• Sotatercept (activin signaling inhibitor): Recommended as add-on treatment for patients already receiving PAH drugs who remain at intermediate-low, intermediate-high, or high risk
• This is based on high certainty evidence from RCTs
• Requires treatment in specialized pulmonary hypertension centers with regular monitoring

Escalation to maximal therapy:

• Current maximal medical therapy is four-drug combination targeting all pathways 13
• Parenteral prostacyclin therapy (epoprostenol, treprostinil) for severe/refractory cases

Important Treatment Caveats

Anticoagulation considerations 14:

• Not routinely recommended in radiation-induced PH if increased bleeding risk exists
• Radiation can cause vascular fragility and increase bleeding complications
• Assess individual risk-benefit ratio

Monitoring requirements for sotatercept 11:

• Must be treated in pulmonary hypertension centers
• Regular follow-up with appropriate examinations
• Monitor for safety and efficacy

Avoid beta-blockers 14:

• Worsen hemodynamics and exercise capacity in PAH patients
• Particularly problematic if used for other radiation-related cardiac complications

Interventional and Surgical Options

Lung transplantation 13:

• Consider for selected patients with inadequate response to maximal medical therapy
• Requires careful evaluation of other radiation-induced cardiac complications (valvular disease, coronary disease, pericardial disease)
• Radiation-induced mediastinal and lung fibrosis may complicate surgery 6

Percutaneous interventions:

• Rarely applicable unless specific anatomic lesions (e.g., pulmonary artery stenosis from radiation) are identified 15

Common Pitfalls to Avoid

1. Delayed diagnosis: PH symptoms are nonspecific (dyspnea, fatigue). Maintain high index of suspicion in patients with mediastinal radiation history.

2. Relying solely on echocardiography: Always confirm with RHC before initiating PAH-specific therapy 9.

3. Missing CTEPH: V/Q scan is essential to exclude chronic thromboembolic disease, which requires different management (anticoagulation, pulmonary endarterectomy) 10, 8.

4. Attributing symptoms only to lung fibrosis: Radiation-induced PH can occur independently of significant parenchymal lung disease 5.

5. Undertreating based on functional class: Even patients in WHO functional class II may benefit from combination therapy. Risk stratification should guide treatment intensity, not functional class alone.

6. Discontinuing therapy prematurely: Unlike trastuzumab-induced cardiotoxicity, radiation-induced vascular injury is typically irreversible. Continue therapy indefinitely unless contraindications develop 7.

7. Ignoring other radiation-induced cardiac complications: These patients often have concurrent coronary disease, valvular abnormalities, pericardial disease, and conduction abnormalities that require comprehensive cardiac evaluation 6, 16.

Multidisciplinary Management

Optimal care requires collaboration between:

• Pulmonary hypertension specialists
• Cardio-oncology team
• Radiation oncologists (for future patients)
• Heart failure specialists
• Interventional cardiologists (for coronary disease management)

All patients with history of mediastinal radiation should be managed in or have access to specialized pulmonary hypertension centers for optimal outcomes 11.